Compare HTBK & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTBK | VIR |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 667.4M | 773.5M |
| IPO Year | 1998 | 2019 |
| Metric | HTBK | VIR |
|---|---|---|
| Price | $11.96 | $6.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $11.88 | ★ $25.73 |
| AVG Volume (30 Days) | 361.3K | ★ 1.8M |
| Earning Date | 01-22-2026 | 11-05-2025 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $187,676,000.00 | $16,860,000.00 |
| Revenue This Year | $13.16 | N/A |
| Revenue Next Year | $7.61 | $48.05 |
| P/E Ratio | $16.48 | ★ N/A |
| Revenue Growth | ★ 10.94 | N/A |
| 52 Week Low | $8.09 | $4.16 |
| 52 Week High | $11.71 | $14.45 |
| Indicator | HTBK | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 76.48 | 60.07 |
| Support Level | $11.06 | $5.45 |
| Resistance Level | $11.48 | $7.06 |
| Average True Range (ATR) | 0.26 | 0.47 |
| MACD | 0.08 | 0.07 |
| Stochastic Oscillator | 96.53 | 74.22 |
Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two reportable segments, namely Banking and Factoring. A majority of its revenue is generated from the Banking segment, which provides various loan products, including commercial and industrial loans, commercial real estate loans, construction loans, etc. This segment also focuses on deposit generation on relationship accounts, encompassing non-interest bearing demand, interest bearing demand, money market accounts, certificates of deposit, and savings accounts.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.